Hunter Cancer Centre
Part of Ramsay Health Care

Radiation Oncologist

Peter O'brien

Associate Professor Peter O'Brien

Radiation Oncologist

Peter O'Brien is a radiation oncologist with more than 20 years' experience in the treatment of cancer and research into improving treatment. He has a particular interest in the management of breast and gynaecological cancer, sarcoma and lymphoma and is actively involved with multi-disciplinary care for all of these tumour types.

Peter has authored more than 60 scientific peer reviewed papers and book chapters and is a reviewer for a number of international journals. He collaborates in current clinical trials and for many years was the Scientific Advisor for the Trans Tasman Radiation Oncology Group receiving the "Outstanding Contribution Award" for his efforts in research. More recently he was appointed to the local therapies group of the Australian and New Zealand Breast Cancer Trials Group and has been an invited speaker at a number of national and international scientific forums.

Training, teaching and mentoring have formed an important part of his professional role and he has been an examiner for the Faculty of Radiation Oncology (RANZCR) and a Board Member. Quality Assurance in daily practice and clinical trials has become an increasing area of interest particularly with increasing complexity in radiation oncology.


Anne Capp

Dr Anne Capp

Radiation Oncologist

Dr Anne Capp is a Radiation Oncologist, with a staff specialist appointment at Calvary Mater Newcastle and a conjoint senior lecturer position with the Faculty of Health and Medicine, University of Newcastle. She is a clinician with subspeciality interests in urological, gastro-intestinal, breast and lymphoma malignancies; and has actively recruited patients from these areas onto a number of multi-centre clinical trials. She is currently Radiotherapy Lead of the Gynae-oncology/Brachytherapy clinical stream.

Previous posts include Director of the Department of Radiation Oncology, Calvary Mater Newcastle from 2010 to 2012, staff specialist at Illawarra Cancer Care Centre, Wollongong Hospital from 1997 to 2006, and Clinical Research Fellow, Royal Marsden Hospital, United Kingdom from 1994 to 1997. She is actively involved in clinical trials both as a recruiter of patients and through the TROG group as quality assurance reviewer for several trials. She completed her undergraduate training at the University of Tasmania in 1987. She undertook her radiation oncology training at St Vincents Hospital and St George Hospital, Sydney, and has both Australian and United Kingdom fellowships. She has also completed a Masters of Medicine in Clinical Epidemiology through the University of Sydney.


Mike Fay

Dr Mike Fay

MBChB, FRACP, FRANZCR
Genesis CancerCare Newcastle

Dr Fay is a dual trained Medical and Radiation Oncologist who specialises in neuro-oncology, stereotactic radiosurgery, thoracic and gastrointestinal oncology.

He completed his undergraduate degree Medicine and Surgery at University of Otago 1993 and is currently completing his PhD on integrating advanced imagery into brain tumour treatment.

Dr Fay has carried out extensive research with a particular focus on brain tumours and the development of new imaging and treatment techniques and is the principal investigator in a number of international cancer trials and collaborations with Canada, the UK and Germany. His research spans across several modalities including PET imagery, MRI imaging and developing multiplexed neuro-imaging techniques. As well as securing over $4.5m in research funding over the last ten years, he is a lead researcher in an NCIC trial into brain tumour treatment in elderly patients. A current research project centres on developing a new PET tracer for use in brain tumours.

Dr Fay has two published book chapters has almost 50 publications on both lung and neuro oncology and alongside his commitment to research he is a senior lecturer at the University of Queensland and a conjoint senior lecturer at the University of Newcastle. He is also an active member of ASCO, ASTRO and COGNO and on the editorial board of The Journal of Translational Lung Cancer Research.


Jarad Martin

Assoc Prof. Jarad Martin

BSc MBChB DMed (Research), FRANZCR GAustMS

A/Prof Jarad Martin is a radiation oncologist with strong research interests. He subspecialises in the multidisciplinary management of gastrointestinal tumours (including tumours of the oesophagus, stomach, pancreas, colon, rectum and anal canal) as well as genitourinary malignancies (including prostate and bladder cancers). A more recent interest is the use of low dose radiotherapy for conditions such as plantar fasciitis and Dupuytren’s contracture.

Jarad attends and contributes to the Newcastle multidisciplinary meetings discussing patients with all of these types of cancer, and has a leading role in helping organise specialist education events in the Hunter region. His technical knowledge is well recognized in areas including image guided radiotherapy (IMRT), image guided radiotherapy (IGRT) and stereotactic radiotherapy (SBRT). Having worked in Victoria, Queensland and Canada prior to commencing practice in Newcastle, he is able to bring a broad perspective to his management of people with cancer.


Katherine NevilleDr Katherine Neville

Dr Neville completed her specialist training at the Calvary Mater Hospital, Royal North Shore Hospital, and Liverpool Hospital before being becoming a Fellow of the Royal Australian and New Zealand College of Radiologists (Faculty of Radiation Oncology) in 2016.

She has received training in the management of all tumour types, however, has a special interest in the treatment of head and neck cancers, breast cancer, lung cancer, benign diseases and the use of radiation for symptom control in advanced cancer.

As well as her clinical interests, Dr Neville has completed research projects in the use of radiotherapy for Mantle Cell Lymphoma, Non-Small Lung Cancer, and Breast Cancer.

She is currently finishing her Masters of Clinical Epidemiology through the University of Newcastle (due completion mid-2018).